INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation
FRA:IUI1 • US46120E6023
Current stock price
388.95 EUR
-13.5 (-3.35%)
Last:
This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IUI1.DE Profitability Analysis
1.1 Basic Checks
- IUI1 had positive earnings in the past year.
- IUI1 had a positive operating cash flow in the past year.
- In the past 5 years IUI1 has always been profitable.
- IUI1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 13.96%, IUI1 belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
- With an excellent Return On Equity value of 16.02%, IUI1 belongs to the best of the industry, outperforming 87.30% of the companies in the same industry.
- IUI1 has a better Return On Invested Capital (13.95%) than 92.06% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IUI1 is above the industry average of 10.21%.
- The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROIC | 13.95% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
1.3 Margins
- The Profit Margin of IUI1 (28.38%) is better than 100.00% of its industry peers.
- In the last couple of years the Profit Margin of IUI1 has grown nicely.
- IUI1's Operating Margin of 29.35% is amongst the best of the industry. IUI1 outperforms 98.41% of its industry peers.
- In the last couple of years the Operating Margin of IUI1 has grown nicely.
- With a decent Gross Margin value of 66.00%, IUI1 is doing good in the industry, outperforming 74.60% of the companies in the same industry.
- In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% |
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
2. IUI1.DE Health Analysis
2.1 Basic Checks
- IUI1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
- IUI1 has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IUI1 has an Altman-Z score of 38.66. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 38.66, IUI1 belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 38.66 |
ROIC/WACC1.56
WACC8.93%
2.3 Liquidity
- A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 4.87, IUI1 belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
- IUI1 has a Quick Ratio of 3.96. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.96, IUI1 belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 |
3. IUI1.DE Growth Analysis
3.1 Past
- IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
- IUI1 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.42% yearly.
- Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
- Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
3.2 Future
- Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
- IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IUI1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 50.91 indicates a quite expensive valuation of IUI1.
- Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than 61.90% of the companies in the same industry.
- When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (26.91), we can say IUI1 is valued expensively.
- A Price/Forward Earnings ratio of 44.47 indicates a quite expensive valuation of IUI1.
- Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 66.67% of the companies in the same industry.
- IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.91 | ||
| Fwd PE | 44.47 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 63.49% of the companies are valued more cheaply.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.81 | ||
| EV/EBITDA | 42.06 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of IUI1 may justify a higher PE ratio.
- IUI1's earnings are expected to grow with 14.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.52
PEG (5Y)2.38
EPS Next 2Y14.34%
EPS Next 3Y14.52%
5. IUI1.DE Dividend Analysis
5.1 Amount
- No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IUI1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IUI1 (4/9/2026, 7:00:00 PM)
388.95
-13.5 (-3.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22 2026-01-22/amc
Earnings (Next)04-21 2026-04-21/amc
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap138.14B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts79.02
Price Target527.49 (35.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)0%
PT rev (3m)0.74%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)0.26%
EPS NY rev (1m)0%
EPS NY rev (3m)3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.91 | ||
| Fwd PE | 44.47 | ||
| P/S | 16.04 | ||
| P/FCF | 64.81 | ||
| P/OCF | 53.27 | ||
| P/B | 9.06 | ||
| P/tB | 9.26 | ||
| EV/EBITDA | 42.06 |
EPS(TTM)7.64
EY1.96%
EPS(NY)8.75
Fwd EY2.25%
FCF(TTM)6
FCFY1.54%
OCF(TTM)7.3
OCFY1.88%
SpS24.25
BVpS42.95
TBVpS42.01
PEG (NY)3.52
PEG (5Y)2.38
Graham Number85.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROCE | 16.01% | ||
| ROIC | 13.95% | ||
| ROICexc | 20.73% | ||
| ROICexgc | 21.4% | ||
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% | ||
| FCFM | 24.75% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 79.72% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.46% | ||
| Profit Quality | 87.21% | ||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z | 38.66 |
F-Score8
WACC8.93%
ROIC/WACC1.56
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.83%
Revenue Next 2Y14.84%
Revenue Next 3Y14.56%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%
INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
What is the profitability of IUI1 stock?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.
How financially healthy is INTUITIVE SURGICAL INC?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.
What is the expected EPS growth for INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 14.45% in the next year.